In our Sunday newsletter, we, as editors, look back on the past seven days. We do this on the initiative of our cartoonist Albert Jan Rasker. He picks a topic, draws a picture, and we take it from there. This week’s…
ChatGPT is all the rage right now. So much so that we seem to forget what it actually is: a language model. And that means it isn’t suited for all kinds of tasks that other machines are already capable of.…
Alongside his “classic corporate career”, the Danish Kim Baden-Kristensen becomes fascinated by the psychology behind being human. He begins to read more and more books on neuroscience. This is how he discovers “neuroplasticity”: the ability of our brain to change…
The week that marks the first anniversary of the start of the war in Ukraine is a historic one. Monday’s visit to Kyiv by United States president Joe Biden was quickly followed by Russia’s president Vladimir Putin’s speech announcing the…
The last time IO spoke to XYZ Dynamics it was about how they were struggling through the pandemic. XYZ Dynamics’ initial idea was to develop an electric powertrain for vans and convert existing commercial vehicles into a hybrid model. A…
Today (23 February) the House of Representatives will debate the National Program Rural Area (NPLG) and the nitrogen problem. The NPLG states that a new balance is needed between what nature can bear and what we as a society can…
Many companies are very concerned about the labor market’s personnel shortage. This year, the deficit is expected to increase further. The deep tech sector in particular will run into further problems. “The fish pond in the Netherlands is empty. It’s…
On an ordinary morning, after a generous amount of coffee, Bob steps into his living room, where his home office setup is. He recently renovated his house, and the work area is now inside a square capsule. In about an…
This start-up is developing an alternative to synthetic chemical pesticides, which often have toxic side effects. In addition, other prospects are opening up for the use of these active ingredients against pests in the veterinary and human sectors. Biologist Dr.…
Xeltis, a clinical stage medtech company developing living implants that enable the body to restore cardiovascular function, has raised €32 million in a Series D2 equity fundraise. The fundraising has been backed by a syndicate of current and new investors,…